|
Diabetes Mellitus
|
0.390 |
AlteredExpression
|
group |
BEFREE |
Serum vascular adhesion protein-1 is up-regulated in hyperglycemia and is associated with incident diabetes negatively.
|
30022055 |
2019 |
|
Diabetes Mellitus
|
0.390 |
AlteredExpression
|
group |
BEFREE |
A significantly decreased SSAO activity and plasma ET-1 level, as well as obviously increased plasma levels of MA and NO(x)- were observed in the DM + AG and DM + 2-BEA groups in comparison with the DM group (P < 0.01).
|
31182088 |
2019 |
|
Diabetes Mellitus
|
0.390 |
Biomarker
|
group |
BEFREE |
VAP-1 has been strongly implicated in several pathological processes, including diabetes, inflammation, hypertension, hepatic steatosis and renal diseases, and is an important disease marker and therapeutic target.
|
29364582 |
2018 |
|
Diabetes Mellitus
|
0.390 |
Biomarker
|
group |
BEFREE |
Vascular adhesion protein-1 (VAP-1) is secreted by vascular smooth muscle cells, adipocytes and endothelial cells with functional monoamine oxidase activity and is elevated in atherosclerosis, diabetes mellitus and obesity.
|
28044236 |
2017 |
|
Diabetes Mellitus
|
0.390 |
Biomarker
|
group |
BEFREE |
The effect of interaction between SSAO and ACE in DM complication is of interest.
|
18413170 |
2009 |
|
Diabetes Mellitus
|
0.390 |
AlteredExpression
|
group |
BEFREE |
It is possible that the increased SSAO activity in diabetes may be a result of up-regulation due to increase of SSAO substrates, such as methylamine or aminoacetone.
|
16487546 |
2006 |
|
Diabetes Mellitus
|
0.390 |
Biomarker
|
group |
BEFREE |
Plasma SSAO correlated positively with duration of diabetes, HbA(1)c and plasma renin, and negatively with plasma angiotensinogen and body mass index.
|
15830186 |
2005 |
|
Diabetes Mellitus
|
0.390 |
AlteredExpression
|
group |
BEFREE |
The increased SSAO activity in diabetes is most likely dependent on post-transcriptional modifications or activation of existing inactive enzyme molecules.
|
15541390 |
2004 |
|
Diabetes Mellitus
|
0.390 |
Biomarker
|
group |
BEFREE |
No wild-type animals displayed this phenotype.In conclusion, we suggest that this transgenic mouse model may be of great value for increasing the knowledge about to what extent human SSAO contributes to vascular complications in diabetes, and also to which extent inhibition of SSAO can prevent the development of such complications.
|
12686114 |
2003 |
|
Chronic Kidney Diseases
|
0.330 |
AlteredExpression
|
group |
BEFREE |
Receiver-operating characteristic curve analyses demonstrated best performance for vascular adhesion protein-1 levels at 12 hours for acute kidney injury within 72 hours after surgery, especially in the subgroup of patients with chronic kidney disease (area under the receiver-operating characteristic curve, 0.78; P < .001).
|
31743166 |
2019 |
|
Chronic Kidney Diseases
|
0.330 |
AlteredExpression
|
group |
BEFREE |
Receiver-operating characteristic curve analyses demonstrated best performance for vascular adhesion protein-1 levels at 12 hours for acute kidney injury within 72 hours after surgery, especially in the subgroup of patients with chronic kidney disease (area under the receiver-operating characteristic curve, 0.78; P < .001).
|
30633060 |
2019 |
|
Chronic Kidney Diseases
|
0.330 |
Biomarker
|
group |
BEFREE |
The ALBUM trial investigated the efficacy of a novel, orally active inhibitor of vascular adhesion protein-1, ASP8232, compared with placebo for reducing albuminuria in individuals with type 2 diabetes and chronic kidney disease.
|
30413396 |
2018 |
|
Hypertensive disease
|
0.320 |
AlteredExpression
|
group |
BEFREE |
We carried out a genomic-wide linkage scan for the quantitative trait locus of circulating VAP-1 levels in 1,100 Han Chinese individuals from 398 families in the Stanford Asian Pacific Program for Hypertension and Insulin Resistance study.
|
29364582 |
2018 |
|
Diabetic Nephropathy
|
0.320 |
Biomarker
|
disease |
BEFREE |
Vascular adhesion protein-1 (VAP-1) is a promising therapeutic target for the treatment of diabetic nephropathy.
|
28601507 |
2017 |
|
Diabetic Nephropathy
|
0.320 |
Biomarker
|
disease |
BEFREE |
Vascular adhesion protein-1 (VAP-1) is a promising therapeutic target for the treatment of diabetic nephropathy.
|
28988626 |
2017 |
|
Hypertensive disease
|
0.320 |
Biomarker
|
group |
BEFREE |
Plasma SSAO was higher in the group with late complications or hypertension, and in patients treated with ACE-inhibitors.
|
15830186 |
2005 |
|
Obesity
|
0.230 |
Biomarker
|
disease |
BEFREE |
Vascular adhesion protein-1 (VAP-1) is secreted by vascular smooth muscle cells, adipocytes and endothelial cells with functional monoamine oxidase activity and is elevated in atherosclerosis, diabetes mellitus and obesity.
|
28044236 |
2017 |
|
Obesity
|
0.230 |
Biomarker
|
disease |
BEFREE |
Finally, the demonstrated AOC3 turnover of primary amines that are non-native to human tissue suggests possible roles for the adipocyte enzyme in subcutaneous bacterial infiltration and obesity.
|
22238597 |
2012 |
|
Obesity
|
0.230 |
Biomarker
|
disease |
BEFREE |
These findings suggest that, although manipulation of VAP-1/SSAO has potential to serve as a therapeutic treatment in insulin-resistant conditions, care must be taken to fully understand its impact on obesity and vascular damage.
|
14977883 |
2004 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.220 |
Biomarker
|
disease |
BEFREE |
Plasma semicarbazide-sensitive amine oxidase (SSAO) is elevated in patients with type 1 and type 2 diabetes and has been implicated in the pathophysiology of diabetic late complications.
|
15830186 |
2005 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.220 |
AlteredExpression
|
disease |
BEFREE |
It has been speculated that production of cytotoxic products of SSAO may cause endothelial damage and thus contribute to the development of diabetic vascular complications such as retino-, nephro-, and neuropathies as a result of SSAO activity.In order to explore the possibility that high SSAO activity contributes to the development of vascular complications in diabetes, we have performed two studies in patients with Type-2 diabetes quantifying plasma SSAO activity, HbA(1c), and urinary levels of the SSAO substrate, methylamine.
|
12686114 |
2003 |
|
Diabetes
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Serum vascular adhesion protein-1 is up-regulated in hyperglycemia and is associated with incident diabetes negatively.
|
30022055 |
2019 |
|
Diabetes
|
0.070 |
Biomarker
|
disease |
BEFREE |
VAP-1 has been strongly implicated in several pathological processes, including diabetes, inflammation, hypertension, hepatic steatosis and renal diseases, and is an important disease marker and therapeutic target.
|
29364582 |
2018 |
|
Diabetes
|
0.070 |
Biomarker
|
disease |
BEFREE |
Synergistic interaction between semicarbazide-sensitive amine oxidase and angiotensin-converting enzyme in diabetes: functional analysis by gene ontology.
|
18413170 |
2009 |
|
Diabetes
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
It is possible that the increased SSAO activity in diabetes may be a result of up-regulation due to increase of SSAO substrates, such as methylamine or aminoacetone.
|
16487546 |
2006 |